Search in:

Neuropsychiatric Disease and Treatment Volume 15, 2019 - Issue

Submit an article Journal homepage

Open access

134

Views

CrossRef citations to date

Altmetric

Original Research

Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)

John M Zajecka1 Department of Psychiatry, Rush University Medical Center, Chicago, IL, USA, [email protected];2 Psychiatric Medicine Associates, LLC, Skokie, IL, USA, [email protected]Correspondence[email protected]

Arielle D Stanford3 Department of Clinical Research, Alkermes, Inc., Waltham, MA, USA

Asli Memisoglu4 Department of Biostatistics, Alkermes, Inc., Waltham, MA, USA

William F Martin5 Clinical Operations, Alkermes, Inc., Waltham, MA, USA

Sanjeev Pathak3 Department of Clinical Research, Alkermes, Inc., Waltham, MA, USA

Pages 795-808 | Published online: 04 Apr 2019

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (17)

Natalie B. Riblet, Yinong Young-Xu, Brian Shiner, Paula P. Schnurr & Bradley V. Watts. (2023) The efficacy and safety of buprenorphine for the treatment of depression: A systematic review and meta-analysis. Journal of Psychiatric Research 161, pages 393-401.
Crossref

Keith M. Olson, Todd M. Hillhouse, Gwendolyn E. Burgess, Joshua L. West, James E. Hallahan, Isaac J. Dripps, Allison G. Ladetto, Kenner C. Rice, Emily M. Jutkiewicz & John R. Traynor. (2023) Delta Opioid Receptor-Mediated Antidepressant-Like Effects of Diprenorphine in Mice. Journal of Pharmacology and Experimental Therapeutics 384:3, pages 343-352.
Crossref

Brandi Quintanilla, Gustavo C. Medeiros, Dede Greenstein, Peixiong Yuan, Jenessa N. Johnston, Lawrence T. Park, Fernando S. Goes, Todd D. Gould & Carlos A. Zarate. (2023) κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine. Journal of Clinical Psychopharmacology 43:2, pages 89-96.
Crossref

Christoph U. Correll, Marco Solmi, Samuele Cortese, Maurizio Fava, Mikkel Højlund, Helena C. Kraemer, Roger S. McIntyre, Daniel S. Pine, Lon S. Schneider & John M. Kane. (2023) The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents. World Psychiatry 22:1, pages 48-74.
Crossref

Kyle J. NealeMelissa B. WeimerMellar P. DavisKatie Fitzgerald JonesJustin G. KullgrenSachin S. KaleJulie ChildersKathleen Broglio, Jessica S. MerlinSarah PeckSheria Y. FrancisJacqueline BangoChristopher A. JonesZachary SagerJ. Janet Ho. (2023) Top Ten Tips Palliative Care Clinicians Should Know About Buprenorphine. Journal of Palliative Medicine 26:1, pages 120-130.
Crossref

Julio Rodríguez-Lavado, Jazmín Alarcón-Espósito, Michael Mallea & Alejandro Lorente. (2022) A New Paradigm Shift in Antidepressant Therapy: From Dual-action to Multitarget-directed Ligands. Current Medicinal Chemistry 29:29, pages 4896-4922.
Crossref

Luke A. Jelen, James M. Stone, Allan H. Young & Mitul A. Mehta. (2022) The opioid system in depression. Neuroscience & Biobehavioral Reviews 140, pages 104800.
Crossref

Octavian Vasiliu. (2022) Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents. Frontiers in Pharmacology 13.
Crossref

Elias Elias, Ariel Y. Zhang & Melissa T. Manners. (2022) Novel Pharmacological Approaches to the Treatment of Depression. Life 12:2, pages 196.
Crossref

Kesheng Wang, Toni DiChiacchio, Wei Fang, Laura Lander, Judith Feinberg, Changchun Xie, Erin L. Winstanley & Ubolrat Piamjariyakul. (2022) Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale. Journal of Affective Disorders 297, pages 148-155.
Crossref

Richard J. Bodnar. (2021) Endogenous opiates and behavior: 2019. Peptides 141, pages 170547.
Crossref

Ruth Bartelli Grigolon, Alisson P. Trevizol, Fernando Gerchman, Alexander D. Bambokian, Taylor Magee, Roger S. McIntyre, Fabiano A. Gomes, Elisa Brietzke & Rodrigo B. Mansur. (2021) Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression.. Journal of Affective Disorders 287, pages 54-68.
Crossref

Catherine Cahill, Hugo A. Tejeda, Mariana Spetea, Chongguang Chen & Lee-Yuan Liu-Chen. 2022. The Kappa Opioid Receptor. The Kappa Opioid Receptor 3 21 .

Peter M. Haddad, David J. Nutt & A. Richard Green. 2020. Seminars in Clinical Psychopharmacology. Seminars in Clinical Psychopharmacology 1 34 .

Adam Dinoff, Sean T. Lynch, Nitin Sekhri & Lidia Klepacz. (2020) A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression. Journal of Affective Disorders 271, pages 91-99.
Crossref

Caitlin A. Madison & Shoshana Eitan. (2020) Buprenorphine: prospective novel therapy for depression and PTSD. Psychological Medicine 50:6, pages 881-893.
Crossref

Caroline A. Browne, Moriah L. Jacobson & Irwin Lucki. (2020) Novel Targets to Treat Depression: Opioid-Based Therapeutics. Harvard Review of Psychiatry 28:1, pages 40-59.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)

Articles from other publishers (17)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)

Citations (17)

Articles from other publishers (17)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date